Postop inflammation & pain drug launched

Article

Durezol 0.05% (difluprednate ophthalmic emulsion; Sirion Therapeutics Inc), a topical corticosteroid to treat postoperative ocular inflammation and pain, is now commercially available, following FDA approval in June 2008.

Durezol 0.05% (difluprednate ophthalmic emulsion; Sirion Therapeutics Inc), a topical corticosteroid to treat postoperative ocular inflammation and pain, is now commercially available, following FDA approval in June 2008.

Durezol has demonstrated, during trials held in Japan and the US, an effective reduction in pain and inflammation amongst subjects suffering inflammation of ≥10 anterior chamber cells, without increasing intraocular pressure (IOP) outside of normal levels. Durezol is administered to the conjunctival sac four times daily for two weeks (beginning 24 hours after surgery) and twice daily for a further week.

Sirion is currently conducting Phase III trials to evaluate Durezol in other ocular conditions, including anterior uveitis. Results of a Phase IIIb trial assessing the efficacy of the drug for the treatment of postoperative ocular inflammation and pain when administered 24 hours prior to surgery have shown that preoperative administration of Durezol is more effective than placebo for reducing ocular pain as early as three or four days after surgery; superiority was maintained until Day 28, regardless of whether Durezol was dosed two or four times daily.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.